<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
    <link rel="stylesheet" href="../css/uswds.min.css">
    <link rel="stylesheet" href="../css/style.css">
    <link rel="stylesheet" href="css/uswds.min.css">
    <link rel="stylesheet" href="css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/html/titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/html/parts/21CFR814.html">Part 814
                                </a><span>&nbsp/&nbsp<span>
                                Sec.  814.82  Postapproval requirements.
                            </h3>
                            <p class="depth1"><em>(a)</em> FDA may impose postapproval requirements in a PMA approval order or by regulation at the time of approval of the PMA or by regulation subsequent to approval. Postapproval requirements may include as a condition to approval of the device:</p><p class="depth2"><em>(1)</em> Restriction of the sale, distribution, or use of the device as provided by section 515(d)(1)(B)(ii) or 520(e) of the act.</p><p class="depth2"><em>(2)</em> Continuing evaluation and periodic reporting on the safety, effectiveness, and reliability of the device for its intended use. FDA will state in the PMA approval order the reason or purpose for such requirement and the number of patients to be evaluated and the reports required to be submitted.</p><p class="depth2"><em>(3)</em> Prominent display in the labeling of a device and in the advertising of any restricted device of warnings, hazards, or precautions important for the device's safe and effective use, including patient information, e.g., information provided to the patient on alternative modes of therapy and on risks and benefits associated with the use of the device.</p><p class="depth2"><em>(4)</em> Inclusion of identification codes on the device or its labeling, or in the case of an implant, on cards given to patients if necessary to protect the public health.</p><p class="depth2"><em>(5)</em> Maintenance of records that will enable the applicant to submit to FDA information needed to trace patients if such information is necessary to protect the public health. Under section 519(a)(4) of the act, FDA will require that the identity of any patient be disclosed in records maintained under this paragraph only to the extent required for the medical welfare of the individual, to determine the safety or effectiveness of the device, or to verify a record, report, or information submitted to the agency.</p><p class="depth2"><em>(6)</em> Maintenance of records for specified periods of time and organization and indexing of records into identifiable files to enable FDA to determine whether there is reasonable assurance of the continued safety and effectiveness of the device.</p><p class="depth2"><em>(7)</em> Submission to FDA at intervals specified in the approval order of periodic reports containing the information required by Sec.  814.84(b).</p><p class="depth2"><em>(8)</em> Batch testing of the device.</p><p class="depth2"><em>(9)</em> Such other requirements as FDA determines are necessary to provide reasonable assurance, or continued reasonable assurance, of the safety and effectiveness of the device.</p><p class="depth1"><em>(b)</em> An applicant shall grant to FDA access to any records and reports required under the provisions of this part, and shall permit authorized FDA employees to copy and verify such records and reports and to inspect at a reasonable time and in a reasonable manner all manufacturing facilities to verify that the device is being manufactured, stored, labeled, and shipped under approved conditions.</p><p class="depth1"><em>(c)</em> Failure to comply with any postapproval requirement constitutes a ground for withdrawal of approval of a PMA.
(Approved by the Office of Management and Budget under control number 0910-0231)
[51 FR 26364, July 22, 1986, as amended at 51 FR 43344, Dec. 2, 1986]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>. Code available <a href="#">on Github.</a></h5>
      </div>
    </div>
  </footer>
  </body>
</html>
